Trial Profile
Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; Clopidogrel (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Pharmacodynamics
- 29 Jan 2024 Planned End Date changed from 31 Mar 2024 to 30 Jun 2024.
- 29 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Mar 2024.
- 10 Aug 2023 Planned End Date changed from 31 Dec 2023 to 31 Mar 2024.